Recent FDA approvals include treatments for chronic migraine, type 1 diabetes, blood cancers, tardive dyskinesia and chorea associated with Huntington disease, vasomotor symptoms of menopause, pain and fever, and Fabry disease.
In an oral presentation at the 2023 ONA Summit, a thoracic oncology nurse practitioner reviewed the advances in the treatment of NSCLC and management of related adverse effects.
A discussion of new treatment options that have improved prognosis for patients with bladder cancer and renal cell carcinoma is the focus of a presentation at the 2023 ONA Summit.
March FDA approvals include treatments for candidemia and invasive candidiasis, sleep apnea for children with Down syndrome, pediatric BRAF V600E low-grade glioma, and migraines.
Identifying limitations in functional reserves in the older adult leads to improved decision-making related to cardiovascular risk stratification and elective procedures.